Fulton Bank N.A. Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fulton Bank N.A. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 56,840 shares of the company’s stock after selling 2,800 shares during the quarter. Fulton Bank N.A.’s holdings in Johnson & Johnson were worth $7,354,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $26,000. Crewe Advisors LLC grew its position in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares in the last quarter. Permanens Capital L.P. grew its position in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares in the last quarter. Finally, Thor Advisors LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $69,000. Institutional investors and hedge funds own 72.01% of the company’s stock.

Johnson & Johnson stock traded down $0.73 during mid-day trading on Thursday, hitting $131.27. 2,915,759 shares of the company’s stock traded hands, compared to its average volume of 6,210,075. The firm has a 50 day moving average price of $129.81 and a 200 day moving average price of $135.22. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The company has a market cap of $341.46 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 2.19 and a beta of 0.69. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.10 EPS. On average, analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.89%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.

Several brokerages have recently commented on JNJ. Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Raymond James decreased their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research report on Wednesday, July 17th. Bank of America reiterated a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Morgan Stanley restated an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Options Trading – Understanding Strike Price

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.